Lansoprazolsulfon-13C6

Lansoprazole sulfone-13C6 (AG-1813-13C6) is 13C labeled Lansoprazole sulfone. Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease[1][2].

1261398-50-8

AG-1813-13C6

12352005

Drug Metabolite; Isotope-Labeled Compounds; Proton Pump

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Others

Metabolism-protein/nucleotide metabolism

Metabolic Disease

CC(C(OCC(F)(F)F)=CC=N1)=C1CS(=O)(C2=N[13C]3=[13CH][13CH]=[13CH][13CH]=[13C]3N2)=O

C10 13C6H14F3N3O3S

391.32

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Swamy G, et al. Crystal structure of lansoprazole sulfone[J]. Journal of Structural Chemistry, 2007, 48: 715-718.|[3]Karol MD, et al. Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. Clin Pharmacol Ther. 1997 Apr;61 (4) :450-8.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W008614S1/

Isotope-Labeled Compounds

No Development Reported